DON M. BAILEY - Corporate Board Profile

Lineage Cell Therapeutics, Inc.

Filing Date	Source Excerpt
2019-06-14	Don M. Bailey. Mr. Bailey previously served as a director and Chairman of Asterias Biotherapeutics, Inc. from February 2016 until our acquisition of Asterias in March 2019. ... Mr. Bailey serves on the board of the Business School at Chapman University in Orange, CA and is a founding board member of the University of California Irvine’s (UCI) Applied Innovation Institute. Mr. Bailey brings to our Board significant knowledge of the pharmaceuticals industry and extensive experience as an executive and board member of publicly traded pharmaceutical companies. ... Committees: Audit, Nominating & Corporate Governance.
2020-08-07	Don M. Bailey previously served as a director and Chairman of Asterias Biotherapeutics, Inc. ... The members of our Nominating and Corporate Governance Committee are Don M. Bailey (Chair), Deborah Andrews, Neal C. Bradsher, and Michael H. Mulroy. ... The members of our Audit Committee are Deborah Andrews (Chair), Don M. Bailey, and Angus C. Russell. ... The members of our Financial Strategy Committee are Alfred D. Kingsley (Chair), Don M. Bailey, Neal C. Bradsher, and Michael H. Mulroy. ... Don M. Bailey $43,477 Fees Earned or Paid in Cash, $76,553 Option Award, $120,030 Total.
2021-08-03	Don M. Bailey. Mr. Bailey previously served as a director and Chairman of Asterias Biotherapeutics, Inc. (AST) from February 2016 until our acquisition of Asterias in March 2019. ... Mr. Bailey brings to our Board significant knowledge of the pharmaceuticals industry and extensive experience as an executive and board member of publicly traded pharmaceutical companies.
2022-04-29	Don M. Bailey. Mr. Bailey previously served as a director and Chairman of Asterias Biotherapeutics, Inc. (AST) from February 2016 until our acquisition of Asterias in March 2019. ... Mr. Bailey brings to our Board significant knowledge of the pharmaceuticals industry and extensive experience as an executive and board member of publicly traded pharmaceutical companies. ... The following table summarizes certain information concerning the compensation during our fiscal year ended December 31, 2021 to each person who served as a non-employee director during the year and who was not our employee on the date the compensation was earned. ... Don M. Bailey $52,000 Fees Earned or Paid in Cash, $89,555 Option Award, $141,555 Total.
2023-07-27	Don M. Bailey. Mr. Bailey previously served as a director and Chairman of Asterias Biotherapeutics, Inc. (AST) ... Mr. Bailey brings to our Board significant knowledge of the pharmaceuticals industry and extensive experience as an executive and board member of publicly traded pharmaceutical companies. ... The table below shows the average annual cash fees for 2022 and the current cash fees, which became effective as of April 1, 2023. ... The following table summarizes certain information concerning the compensation during our fiscal year ended December 31, 2022 to each person who served as a non-employee director during the year and who was not our employee on the date the compensation was earned. ... Don M. Bailey $54,750 Fees Earned or Paid in Cash, $78,500 Option Award, $133,250 Total.
2024-04-29	Don M. Bailey. Mr. Bailey previously served as a director and Chairman of Asterias Biotherapeutics, Inc. ... Our Board has determined that Ms. Andrews, Dr. Amin, Mr. Bailey, Mr. Bradsher, Dr. Jayasuriya, Mr. Mulroy, and Mr. Russell qualify as “independent” directors ... The table below sets forth the composition of the committees of our Board as of April 25, 2024: ... Don M. Bailey: Audit Committee Member, Compensation Committee Member ... 2023 Non-Employee Director Compensation Table: Don M. Bailey total $130,500.
2024-12-09	The Audit Committee of our Board, which is comprised solely of independent directors Ms. Andrews, Messrs. Bailey and Mulroy, and Angus C. Russell.